OZEM Roundhill GLP-1 & Weight Loss ETF
Holds 25 stocks in healthcare innovation and GLP-1, 26% of its weight in S&P 500 companies
OZEM holds 25 stocks, and 74% of its weight is outside the S&P 500.
Key facts
ETFIQ Off-Index Score
46.5joint 197th of 371
OZEM shares 4 of its 25 holdings with the S&P 500. Only 2.2% of its weight overlaps the index.
How much of it is not the index it is sold as an alternative to?
That is the share of the 371 thematic ETFs with a holdings filing sitting at or below OZEM. A position in this set, not a rating: it moves when the set moves, and it is not a figure to average against another desk's.
1st of 8 healthcare innovation and glp-1 ETFs by net assets 3rd of 8 healthcare innovation and glp-1 ETFs by least weight in the S&P 500
Its ten largest equity positions
| Holding | Ticker | Weight | |
|---|---|---|---|
| Eli Lilly & Co | LLY | 12.22% | |
| Novo Nordisk A/S | NVO | 12.07% | |
| Pfizer Inc | PFE | 7.62% | |
| CSPC Pharmaceutical Group Ltd | not filed | 6.88% | |
| Viking Therapeutics Inc | VKTX | 4.97% | |
| Hanmi Pharm Co Ltd | not filed | 4.87% | |
| Chugai Pharmaceutical Co Ltd | not filed | 4.21% | |
| Amgen Inc | AMGN | 4.16% | |
| Kailera Therapeutics Inc | KLRA | 4.08% | |
| Zealand Pharma A/S | not filed | 3.97% |
Period by period
| Window | Total return | S&P 500 | Gap to S&P 500 | Gap to Nasdaq-100 |
|---|---|---|---|---|
| 3 months | +1.9% | +3.3% | −1.4 pts | +2.7 pts |
| 6 months | −0.6% | +16.0% | −16.6 pts | −21.3 pts |
| 1 year | +21.1% | +17.5% | +3.6 pts | −1.9 pts |
| Since launch | +24.4% | +47.7% | −23.3 pts | −34.3 pts |
In plain words
The top ten holdings are 65% of the fund across 25 positions, as published by its issuer for Sep 11, 2026. Over the year to Sep 11, 2026 the fund returned +21.1% with distributions reinvested against +17.5% for the S&P 500, so a holder was ahead by 3.6 pts. It sits 15.9% below its all-time high of Jan 26, 2026.
| Theme (ETFIQ, editorial) | Healthcare innovation and GLP-1 |
|---|---|
| Launched | May 21, 2024 |
| Already in the S&P 500, by weight (ETFIQ) | 26.0% |
| Active share vs the S&P 500 (ETFIQ) | 97.8% |
| Already in the Nasdaq-100, by weight (ETFIQ) | 6.2% |
| Active share vs the Nasdaq-100 (ETFIQ) | 98.5% |
| Top ten holdings weight | 65.0% |
| Holdings | 25 |
| Holdings published for (the issuer’s daily file) | Sep 11, 2026 |
| Top holdings | Eli Lilly & Co 12.2%, Novo Nordisk A/S 12.1%, Pfizer Inc 7.6%, CSPC Pharmaceutical Group Ltd 6.9%, Viking Therapeutics Inc 5.0%, Hanmi Pharm Co Ltd 4.9%, Chugai Pharmaceutical Co Ltd 4.2%, Amgen Inc 4.2%, Kailera Therapeutics Inc 4.1%, Zealand Pharma A/S 4.0% |
| Net assets (the issuer own daily fund list, as of Sep 11, 2026) | $58m |
| Below its all-time high (ETFIQ) | −15.9% |
| Expense ratio (485BPOS XBRL, Apr 30, 2026) | 0.59% |
| Fee for the part that differs from the S&P 500, active expense ratio (ETFIQ) | 0.60% |
Holdings from the file the issuer publishes daily; overlap and active share computed by ETFIQ against the IVV and QQQM books; returns from Tiingo end-of-day prices with distributions reinvested. How these figures are computed
Questions people ask
- How much of OZEM is in S&P 500 companies?
- By its holdings published by its issuer for Sep 11, 2026, 26% of OZEM by weight is stocks the S&P 500 already holds. Its active share against the index is 98%, so that share is the part doing something different.
- What does OZEM hold?
- 25 positions as published by its issuer for Sep 11, 2026, with the top ten at 65% of the fund. The largest are Eli Lilly & Co at 12.2%, Novo Nordisk A/S at 12.1%, Pfizer Inc at 7.6%.
- Has OZEM beaten the S&P 500?
- Over the year to Sep 11, 2026 OZEM returned +21.1% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 3.6 points.
- What does OZEM cost?
- The prospectus expense ratio is 0.59% a year. Because 98% of the fund differs from the S&P 500, the fee on that differing part works out at 0.60%.
The words on this page
- Active share
- The part of the fund doing something the index is not, as a percentage. It is the part a fee is actually buying.
- Weight overlap
- The share of money two portfolios hold in the same securities at the same weight. Above 50%, holding both is close to holding one of them twice.
- Already in the index
- The fund’s weight in securities the S&P 500 holds at all. A fund can be made entirely of index names and still have high active share, because it holds them at very different weights.
- Top ten
- What the ten largest positions add up to. The higher it is, the more the fund is a bet on a few companies rather than a theme.
Every term used here, defined in full on the thematic ETFs vocabulary page.
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Funds near this one
Put this on your own page
The difference bar for OZEM, redrawn every trading night. Free to use with the credit link.
Where OZEM is written about
Use this data, or open the live card
Open OZEM live on ETFIQ, where the figures refresh with the data.
Cite this page. ETFIQ, OZEM, thematic ETFs, data as of Sep 11, 2026. https://etfiq.com/funds/ozem Free to use with attribution; the underlying files are at Open data.